ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.60
0.71%
US Tech 100
19,636.04
0.55%
S&P 500
5,770.20
0.55%
US Dollar vs CAD
1.43715
0.00%
Bitcoin
81,318.40
-5.61%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. argenx SE (ARGX)

  7. argenx SE (ARGX) News

ARGX

argenx (ARGX)

argenx SE
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARGX
DateTimeSourceHeadlineSymbolCompany
03/07/20255:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
03/07/202512:00AMGlobeNewswire Inc.argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual MeetingNASDAQ:ARGXargenx SE
02/27/20255:34AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
02/27/202512:00AMGlobeNewswire Inc.argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business UpdateNASDAQ:ARGXargenx SE
02/25/202512:00AMGlobeNewswire Inc.argenx to Present at TD Cowen 45th Annual Healthcare ConferenceNASDAQ:ARGXargenx SE
02/20/202512:00AMGlobeNewswire Inc.argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025NASDAQ:ARGXargenx SE
02/12/20258:16AMEdgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ARGXargenx SE
01/13/202512:00AMGlobeNewswire Inc.argenx Highlights 2025 Strategic PrioritiesNASDAQ:ARGXargenx SE
01/06/202512:00AMGlobeNewswire Inc.argenx to Present at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ARGXargenx SE
12/27/20245:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
12/27/202412:00AMGlobeNewswire Inc.argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating PolyneuropathyNASDAQ:ARGXargenx SE
11/26/202412:00AMGlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesNASDAQ:ARGXargenx SE
11/20/20245:35AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
11/20/202412:00AMGlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory MyopathiesNASDAQ:ARGXargenx SE
11/12/20245:35AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
11/11/20246:30AMGlobeNewswire Inc.argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in ChinaNASDAQ:ARGXargenx SE
11/11/20246:30AMBusiness WireZai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in ChinaNASDAQ:ARGXargenx SE
11/05/202412:00AMGlobeNewswire Inc.argenx to Participate at Upcoming Investor ConferencesNASDAQ:ARGXargenx SE
10/31/20247:15AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
10/31/20241:00AMGlobeNewswire Inc.argenx Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARGXargenx SE
10/24/202412:00AMGlobeNewswire Inc.argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024NASDAQ:ARGXargenx SE
10/15/20247:14AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
10/15/202412:00AMGlobeNewswire Inc.argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific SessionsNASDAQ:ARGXargenx SE
09/19/20245:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
09/19/202412:00AMGlobeNewswire Inc.argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating PolyneuropathyNASDAQ:ARGXargenx SE
08/28/202412:00AMGlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesNASDAQ:ARGXargenx SE
07/25/20245:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
07/25/202412:00AMGlobeNewswire Inc.argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business UpdateNASDAQ:ARGXargenx SE
07/18/202412:00AMGlobeNewswire Inc.argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024NASDAQ:ARGXargenx SE
07/16/20244:22PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
 Showing the most relevant articles for your search:NASDAQ:ARGX

Your Recent History

COIN
BTCUSD
Bitcoin
USOTC
AABB
Asia Broadband (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
NASDAQ
AMRN
Amarin
NASDAQ
TSLA
Tesla
NASDAQ
COOP
Mr Cooper
COIN
XRPUSD
Ripple
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
RDGL
Vivos (QB)
NASDAQ
LWLG
Lightwave Logic
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
NWBO
Northwest Biotherapeutics (QB)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
FNMA
Fannie Mae (QB)
USOTC
HMBL
HUMBL (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads